STRATEC SE

Share Issue/Capital Change • Apr 11, 2006

News Details

Corporate | 11 April 2006 10:40

STRATEC plans to issue bonus shares

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC plans to issue bonus shares Birkenfeld, April 11, 2006 The Supervisory Board and Board of Management of STRATEC Biomedical Systems AG, which is listed in the Prime Standard, have decided to propose the execution of a capital increase from company funds and the issuing of bonus shares for approval by the Annual General Meeting on June 23, 2006. The share capital is to be increased in this respect by converting reserves. In the course of this measure, each shareholder is to receive two new shares (bonus shares) for each existing share. No deposit is to be made by the shareholders. By undertaking the capital increase from company funds, STRATEC would like to make its share more attractive for investors and facilitate trading with the share. Should the Annual General Meeting of STRATEC Biomedical Systems AG provide its consent, then following the execution of this measure the volume of STRATEC shares held by shareholders in their securities accounts will automatically treble. This measure has no impact on the volume of shareholders’ equity at the company; it will merely result in a regrouping within the components of shareholders’ equity. Overall, the share capital, which currently amounts to EUR 3,678,345.00, will increase to EUR 11,035,035.00, divided into 11,035,035 individual ordinary bearer shares in the company with a nominal value of EUR 1.00 each. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion’ and ‘Sanguin’. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de (c)DGAP 11.04.2006 ————————————————————————— language: English emitter: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland phone: +49 (0)7082 7916 0 fax: +49 (0)7082 7916 999 email: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 indexes: stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————